Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study

[1]  A. Domínguez-Rodríguez,et al.  Clinical Implications of Elevated Serum Interleukin‐6, Soluble CD40 Ligand, Metalloproteinase‐9, and Tissue Inhibitor of Metalloproteinase‐1 in Patients with Acute ST‐segment Elevation Myocardial Infarction , 2009, Clinical cardiology.

[2]  E. Benjamin,et al.  Relation of smoking status to a panel of inflammatory markers: the framingham offspring. , 2008, Atherosclerosis.

[3]  M. Matsumoto,et al.  Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation , 2008, Heart and Vessels.

[4]  Nader Rifai,et al.  Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. , 2008, European heart journal.

[5]  N. Çam,et al.  Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention , 2008, Heart and Vessels.

[6]  F. Santilli,et al.  CD40/CD40L system and vascular disease , 2007, Internal and emergency medicine.

[7]  A. Youssef,et al.  Association between circulating level of CD40 ligand and angiographic morphologic features indicating high-burden thrombus formation in patients with acute myocardial infarction undergoing primary coronary intervention. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[8]  A. Leone,et al.  Smoking, haemostatic factors, and cardiovascular risk. , 2007, Current pharmaceutical design.

[9]  C. Ting,et al.  The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. , 2006, Metabolism: clinical and experimental.

[10]  P. Libby,et al.  Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[11]  J. J. Griffin,et al.  Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. , 2005, American heart journal.

[12]  M. Furman,et al.  Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. , 2004, Journal of the American College of Cardiology.

[13]  D. Newby,et al.  Upregulation of the CD40/CD40 Ligand Dyad and Platelet-Monocyte Aggregation in Cigarette Smokers , 2004, Circulation.

[14]  P. Libby,et al.  Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.

[15]  J. Freedman.  CD40-CD40L and platelet function: beyond hemostasis. , 2003, Circulation research.

[16]  C. Heeschen,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, New England Journal of Medicine.

[17]  D. Phillips,et al.  Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation , 2003, Circulation.

[18]  Patrick André,et al.  Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.

[19]  R. Hynes,et al.  CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism , 2002, Nature Medicine.

[20]  S. Kulkarni,et al.  Changes in platelet glycoprotein receptors after smoking – a flow cytometric study , 2001, Platelets.

[21]  R. Califf,et al.  Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. , 2000, American heart journal.

[22]  K. Forfang,et al.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. , 1999, Circulation.

[23]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[24]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[25]  M. Yeolekar,et al.  FACTOR V LEIDEN GENE MUTATION IN YOUNG INDIAN PATIENTS WITH MYOCARDIAL INFARCTION , 1998 .

[26]  M. Ishihara,et al.  Clinical implications of cigarette smoking in acute myocardial infarction: acute angiographic findings and long-term prognosis. , 1997, American heart journal.

[27]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[28]  D. Celermajer,et al.  Cigarette Smoking Is Associated With Dose‐Related and Potentially Reversible Impairment of Endothelium‐Dependent Dilation in Healthy Young Adults , 1993, Circulation.

[29]  J. Oates,et al.  Cigarette smoking and hemostatic function. , 1988, American heart journal.

[30]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[31]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[32]  G. Gensini,et al.  A more meaningful scoring system for determining the severity of coronary heart disease. , 1983, The American journal of cardiology.

[33]  H. Jenzer,et al.  Cigarette smoking and coronary heart disease , 2000 .